{"id":968007,"date":"2026-05-28T08:11:38","date_gmt":"2026-05-28T12:11:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/"},"modified":"2026-05-28T08:11:38","modified_gmt":"2026-05-28T12:11:38","slug":"newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/","title":{"rendered":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NAARDEN, the Netherlands and MIAMI, May  28, 2026  (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Jefferies Global Healthcare Conference 2026 <\/strong>in New York, NY on Wednesday, June 3, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 10:30 a.m. ET on Wednesday, June 3.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>Goldman Sachs 47<\/strong><br \/>\n          <sup><br \/>\n            <strong>th<\/strong><br \/>\n          <\/sup><br \/>\n          <strong> Annual Global Healthcare Conference <\/strong>in Miami Beach, FL on Tuesday, June 9, 2026. Michael Davidson, M.D., Chief Executive Officer,\u00a0and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 2:40 p.m. ET on Tuesday, June 9.<\/li>\n<\/ul>\n<p>Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OFxzmMiuNQXd5Ej3c3IPcmrq5Z0SzAIOU-cbAB4rIPxbbvtZJdci3S8h4LeycDx_7lQmoAdS5b2-p4qxEm9CEMsQRONQErfZYlPW2W65HJCG1vlRC9_1tEfVG92g6-rh\" rel=\"nofollow\" target=\"_blank\">ir.newamsterdampharma.com<\/a>. Following the live webcasts, archived replays will be available on the Company\u2019s website.<\/p>\n<p>\n        <strong>About NewAmsterdam<\/strong>\n      <\/p>\n<p>NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.<\/p>\n<p>\n        <strong>Company Contact<br \/><\/strong>Matthew Philippe<br \/>P: 1-917-882-7512<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ygfn9uZ0fS22yo8YsRxA0kK0ovfaUhJ0uu1UA8cgfV4HBBgGRIyacokL09dqx9K2koHuG0_haSrL0sRwjOyPYSMcjqJinCJKXFvu3tLV478mdKbygjPrY6uJUufzV62a2DL73WJjQNNSWqSIvS7HNw==\" rel=\"nofollow\" target=\"_blank\">matthew.philippe@newamsterdampharma.com<\/a><\/p>\n<p>\n        <strong>Media Contact<br \/><\/strong>Real Chemistry on behalf of NewAmsterdam<br \/>Christian Edgington<br \/>P: 1-513-310-6410<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DFE1Nkcxrh6q_jibwQHo8r3l7XWHV9oedGc4_o_0EohRCcKODsBmN06JPLVU4DlX8K8Fqa0GzemXYs579QptNIEY75mYWhzApgpa_Nz8GRtP8boojHi83FaqrF3isipN\" rel=\"nofollow\" target=\"_blank\">cedgington@realchemistry.com<\/a><\/p>\n<p>\n        <strong>Investor Contact<br \/><\/strong>Precision AQ on behalf of NewAmsterdam<br \/>Austin Murtagh<br \/>P: 1-212-698-8696<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WBdxfdug4uXaHg2zrZCQeixKKwCOZ9ybU1luIdxd_rVvpZ_ppxeG20o82vcGJ6agcUev1MuRnbqqoCJW8Cm5vnIildxrvFjjJ4BgPBvOOhvgx2xaq0aG64ppbRUa3GsI\" rel=\"nofollow\" target=\"_blank\">austin.murtagh@precisionaq.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDlhYzUwZjItNWQyOC00MGUyLWEyNGEtYzEyMDAyMmIyMzYyLTEyNjE4OTQtMjAyNi0wNS0yOC1lbg==\/tiny\/NewAmsterdam-Pharma-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference 2026 in New York, NY on Wednesday, June 3, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 10:30 a.m. ET on Wednesday, June 3. Goldman Sachs 47 th Annual Global Healthcare Conference &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-968007","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference 2026 in New York, NY on Wednesday, June 3, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 10:30 a.m. ET on Wednesday, June 3. Goldman Sachs 47 th Annual Global Healthcare Conference &hellip; Continue reading &quot;NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-28T12:11:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June\",\"datePublished\":\"2026-05-28T12:11:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/\"},\"wordCount\":346,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/\",\"name\":\"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=\",\"datePublished\":\"2026-05-28T12:11:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/","og_locale":"en_US","og_type":"article","og_title":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - Market Newsdesk","og_description":"NAARDEN, the Netherlands and MIAMI, May 28, 2026 (GLOBE NEWSWIRE) &#8212; NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or \u201cNewAmsterdam\u201d or the \u201cCompany\u201d), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (\u201cCVD\u201d) with elevated low-density lipoprotein cholesterol (\u201cLDL-C\u201d), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference 2026 in New York, NY on Wednesday, June 3, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 10:30 a.m. ET on Wednesday, June 3. Goldman Sachs 47 th Annual Global Healthcare Conference &hellip; Continue reading \"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-28T12:11:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June","datePublished":"2026-05-28T12:11:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/"},"wordCount":346,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/","name":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=","datePublished":"2026-05-28T12:11:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNzM4MyM3NjIzNDE1IzIyNTAzNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/newamsterdam-pharma-to-participate-at-upcoming-investor-conferences-in-june\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968007","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=968007"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968007\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=968007"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=968007"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=968007"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}